Zimmer Biomet (NYSE: ZBH) lifts 2026 EPS outlook after strong Q1 results

Zimmer Biomet Holdings, Inc. reported strong Q1 2026 results with net sales up 9.3% to $2.087 billion and adjusted diluted EPS increasing 15.5% to $2.09. Following this performance, the company raised its full-year 2026 adjusted diluted EPS guidance to a range of $8.40 to $8.55. The report also detailed solid cash generation, significant share repurchases, and ongoing innovation efforts, while noting a pending final assessment on goodwill impairment which could impact GAAP net earnings.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin